0001856420-21-000001.txt : 20210420
0001856420-21-000001.hdr.sgml : 20210420
20210419191520
ACCESSION NUMBER: 0001856420-21-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20210420
DATE AS OF CHANGE: 20210419
EFFECTIVENESS DATE: 20210420
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Goldilocks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001856420
IRS NUMBER: 825080202
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-396368
FILM NUMBER: 21835852
BUSINESS ADDRESS:
STREET 1: 55 E. FIELD DRIVE
CITY: BEDFORD
STATE: NY
ZIP: 10506
BUSINESS PHONE: (914) 205-3862
MAIL ADDRESS:
STREET 1: 55 E. FIELD DRIVE
CITY: BEDFORD
STATE: NY
ZIP: 10506
D
1
primary_doc.xml
X0708
D
LIVE
0001856420
Goldilocks Therapeutics, Inc.
55 E. FIELD DRIVE
BEDFORD
NY
NEW YORK
10506
(914) 205-3862
DELAWARE
None
None
Corporation
true
2018
Arthur
Klausner
55 E. Field Drive
Bedford
NY
NEW YORK
10506
Executive Officer
Director
Krishna
Polu
55 E. Field Drive
Bedford
NY
NEW YORK
10506
Director
Scott
Minick
55 E. Field Drive
Bedford
NY
NEW YORK
10506
Director
Biotechnology
Decline to Disclose
- 06b
false
2019-12-11
false
true
true
true
true
Convertible notes and the securities into which the notes are convertible (and the securities into which the securities issued upon conversion of the notes are convertible)
false
0
1230883
1230883
0
false
23
0
0
0
false
Goldilocks Therapeutics, Inc.
Arthur Klausner
Arthur Klausner
President and CEO
2021-04-19